Tempest Therapeutics Stock Skyrockets Over 2,100% on Positive Liver Cancer Drug Data

Tempest Therapeutics stock shot up over 2,100% after releasing positive data on its oncology drug TPST-1120 for treating liver cancer.

TPST-1120 combined with two other drugs showed a 30% response rate, much higher than 13.3% with the other drugs alone.

TPST-1120 targets advanced hepatocellular carcinoma, a type of liver cancer.

Tempest implemented a shareholder rights plan, not due to a takeover threat but likely as a precaution.

Prior to the data release, Tempest's share price was flat, then spiked and continued climbing despite a brief dip.